Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

nically significant."

Study discontinuations due to adverse events occurred in 11 (4.8%) of the 229 Fampridine-SR-treated patients, and none of the 72 patient placebo group. Three of these events were considered serious: influenza, sepsis and anxiety. The anxiety was considered probably related to treatment. A focal seizure, observed during the sepsis, was considered possibly related to treatment. An additional 13 patients in the Fampridine-SR-treated group experienced various serious adverse events but none of these led to discontinuation from treatment and none was considered related to treatment. Most non-serious adverse events were rated as mild to moderate in intensity and observed at similar rates in Fampridine-SR and placebo groups. Some events were seen more frequently in the Fampridine-SR group (insomnia, fatigue, back pain, balance disorder) while upper respiratory infection was more common in the placebo group. Overall, the safety data were consistent with previous experience.

Study Design

The double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS. The trial, which enrolled 301 individuals at 33 MS centers in the United States and Canada, recruited patients between 18 and 70 years old with a definite diagnosis of MS and some degree of walking disability. The study was open to people with all types of MS, including primary-progressive, secondary-progressive, relapsing-remitting and progressive-relapsing. Participants were permitted to remain on a stable regimen of their current medications, including immunomodulators. Secondary endpoints for the trial included the Lower Extremity Manual Muscle Test, the Ashworth Score for spasticity, and Subject and Clinician Global Impressions. Subjects were randomized to 14 weeks of treatment with Fampridine-SR (n=229) or placebo (n=72), a 3:1 ratio of drug to placebo. The safety measures in this trial in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... Sept. 17, 2014  Dr. Stephen Loyd , ... House today for National Recovery Month, stars in a ... released today. Consumer advocates were also joined by a ... out after losing her fiancée because of a preventable ... had a history of crack cocaine abuse. Proposition 46 ...
(Date:9/17/2014)... Bronstein, Gewirtz & Grossman, LLC is investigating ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... advised to contact Peretz Bronstein or his ... info@bgandg.com or 212-697-6484. The investigation focuses ... violated federal securities laws. On September 16, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... Virtual CME, LLC , a leading provider in ... of the industry,s first online, image based CME accredited ... of streaming video, 3D visualization cloud computing, and webinars, ... "Realizing that training in medical imaging is a ...
... Va., Aug. 26, 2011 Today, Medicomp Systems announced ... its new version of the powerful MEDCIN Engine®. ... that adapts to the unique clinical presentation of each ... for compliance and reimbursement. The MEDCIN Engine currently includes ...
Cached Medicine Technology:Medicomp Releases ICD-10-CM with New Version of the Powerful MEDCIN Engine® 2
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus Moon, ... vegan and gluten-free Sugar Cane Fruit Mask. Their newest ... skincare testers were looking for. , “My goal ... that provided results, and I think I accomplished it,” ... Mask combines Willow bark (Salix Alba extract), a natural ...
(Date:9/17/2014)... 2014 The in vitro diagnostics (IVD) ... market, focusing on molecular diagnostics for conditions such as ... testing. The IVD market value is projected to be ... 2017. The major drivers of the market’s growth include ... is evidenced by the explosion for raid and minimally-invasive ...
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- Managing diabetes, quitting smoking, ... weight can reduce the risk for dementia -- even ... The World Alzheimer Report 2014, commissioned by Alzheimer,s Disease ... dementia by 50 percent. The study noted that obesity ... diabetes as well as high blood pressure. ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... and dieters who turn to artificial sweeteners to soothe ... favors, a new Israeli study suggests. Artificial sweeteners ... no calories, researchers found in human and mouse studies. ... alter the bacteria residing in the intestines in ways ...
Breaking Medicine News(10 mins):Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3
... may benefit from HPV vaccine, study finds , TUESDAY, June ... for women aged 24 to 45 who aren,t already infected ... cancer and other cervical diseases. , That,s the finding from ... Bogota, Columbia, who noted that women,s rising age at first ...
... 2, 2009 Because bleeding from the reproductive tract ... women who exhibit menorrhagia, or excessive bleeding after their ... In order to address important issues related to the ... with bleeding disorders, a consensus conference was convened. Results ...
... use a new, cutting edge diagnostic technology to fight serious ... , WOBURN, Mass., and VEDBAEK, Denmark, June 2 AdvanDx ... Georgia has implemented AdvanDx,s PNA FISH(R) tests to identify bloodstream ... help their physicians, pharmacists and nurses improve care and outcomes ...
... Reporting Now Available Through CSC,s FirstPortfolio Offering , ... CSC ) today announced that it has ... to include fully integrated Medicare Secondary Payer (MSP) reporting ... of applications hosted and maintained by CSC. , ...
... Couple,s Struggle with Alzheimer,s , , WASHINGTONVILLE, N.Y., June 2 ... over 5 million Americans currently living with Alzheimer,s disease and the ... to announce the release of her book, "Released to the Angels: ... ). , , "Released to the Angels" is an ...
... 2 Rules-Based Medicine, Incorporated (RBM), the leading biomarker ... has joined the Company as vice president, clinical diagnostics. ... as RBM commercializes new biomarker-based diagnostic tests. ... biomarker assays for improved drug development, has programs to ...
Cached Medicine News:Health News:Cervical Cancer Vaccine Not Just for Teens 2Health News:Experts reach consensus on diagnosis and treatment of bleeding disorders in women 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:CSC Offers Medicare Secondary Payer Reporting to Health Plans 2Health News:The Unexpected Gifts of Alzheimer's 2Health News:The Unexpected Gifts of Alzheimer's 3Health News:Rules-Based Medicine, Inc. Names Tony Barnes to Lead Expanding Diagnostics Business 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: